Myomo (MYO)

Executive Summary

Myomo (NYSE: MYO) is a medical device company focused on restoring upper limb function for individuals with paralysis due to neurological conditions or injury. Its flagship product, the MyoPro, is a powered arm orthosis that uses non-invasive myoelectric sensors to detect residual nerve signals and translate them into natural movements. This technology addresses a significant unmet need, as millions of patients with conditions such as stroke, brachial plexus injury, or spinal cord injury suffer from arm paralysis. The MyoPro enables patients to perform activities of daily living, improving their independence and quality of life. The company has established a commercial presence and continues to expand market access. Myomo benefits from a growing awareness of the value of powered orthotics and favorable reimbursement trends. With a solid balance sheet and focused execution, the company is poised for growth through geographic expansion and potential new indications. However, adoption remains constrained by limited insurance coverage and the need for additional clinical evidence. Looking ahead, upcoming catalysts include broadening FDA clearances, strategic partnerships with rehabilitation centers, and potential inclusion in Medicare’s durable medical equipment benefit categories, which could significantly expand the addressable market.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for Pediatric Version of MyoPro70% success
• TBDMedicare Coverage Decision for MyoPro50% success
• Q3 2026Positive Results from Post-Market Clinical Study in Stroke Patients75% success